Naltrexone Products Sample Clauses

Naltrexone Products. As partial consideration for the grant to OPIANT of the rights under Section 3.1 the Parties agree to the following milestones for the first Product containing naltrexone: Successful Completion of the first pilot PK study in humans [***] Upon the Successful Completion of the first PK study in humans; provided, that if OPIANT has not initiated a first PK study in humans by March 31, 2019, then such milestone shall be due on by March 31, 2019 [***] Successful Completion of the first Phase II study [***] Successful Completion of the second Phase III study [***] Approval of the first NDA or its equivalent [***] At the time when any milestone payment listed in the table above is due, if OPIANT has not paid all other milestone payments (if any) previously listed in such table, then at such time OPIANT shall pay all such unpaid previous milestone payments. Notwithstanding the foregoing, in the event that a Product contains two Compounds in combination, then OPIANT shall: (i) pay to Aegis a one-time fee in the amount of [***]; and (ii) upfront milestones payments for the higher of the two Compounds with respect to such Product under Sections 4.1, 4.2.1, 4.2.2 and 4.2.3.